Facciabene A - Search Results

1

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, Carroll RG, Gimotty PA, Hammond R, Danet-Desnoyers GÄ, June CH, Powell DJ Jr, Coukos G. Alagkiozidis I, et al. Among authors: facciabene a. J Transl Med. 2009 Dec 10;7:104. doi: 10.1186/1479-5876-7-104. J Transl Med. 2009. PMID: 20003308 Free PMC article.

2

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O'Brien-Jenkins A, Gimotty PA, Coukos G. Buckanovich RJ, et al. Among authors: facciabene a. Nat Med. 2008 Jan;14(1):28-36. doi: 10.1038/nm1699. Epub 2008 Jan 6. Nat Med. 2008. PMID: 18157142

3

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.

Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Adams SF, et al. Among authors: facciabene a. Cancer. 2009 Jul 1;115(13):2891-902. doi: 10.1002/cncr.24317. Cancer. 2009. PMID: 19472394 Free PMC article.

4

Endothelin B receptor, a new target in cancer immune therapy.

Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Kandalaft LE, et al. Among authors: facciabene a. Clin Cancer Res. 2009 Jul 15;15(14):4521-8. doi: 10.1158/1078-0432.CCR-08-0543. Epub 2009 Jun 30. Clin Cancer Res. 2009. PMID: 19567593 Free PMC article. Review.

5

The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ Jr, Coukos G. Kandalaft LE, et al. Among authors: facciabene a. Gynecol Oncol. 2010 Feb;116(2):222-33. doi: 10.1016/j.ygyno.2009.11.001. Epub 2009 Dec 2. Gynecol Oncol. 2010. PMID: 19959212 Free PMC article. Review.

6

Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.

Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, June CH, Powell DJ Jr, Coukos G. Alagkiozidis I, et al. Among authors: facciabene a. J Transl Med. 2011 May 25;9:77. doi: 10.1186/1479-5876-9-77. J Transl Med. 2011. PMID: 21609494 Free PMC article.

7

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G. Facciabene A, et al. Nature. 2011 Jul 13;475(7355):226-30. doi: 10.1038/nature10169. Nature. 2011. PMID: 21753853

8

T-regulatory cells: key players in tumor immune escape and angiogenesis.

Facciabene A, Motz GT, Coukos G. Facciabene A, et al. Cancer Res. 2012 May 1;72(9):2162-71. doi: 10.1158/0008-5472.CAN-11-3687. Cancer Res. 2012. PMID: 22549946 Free PMC article. Review.

9

Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?

Facciabene A, Santoro S, Coukos G. Facciabene A, et al. Oncoimmunology. 2012 Jul 1;1(4):575-577. doi: 10.4161/onci.19401. Oncoimmunology. 2012. PMID: 22754792 Free PMC article.

10

Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.

Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, Facciabene A. Facciponte JG, et al. Among authors: facciabene a. J Clin Invest. 2014 Apr;124(4):1497-511. doi: 10.1172/JCI67382. Epub 2014 Mar 18. J Clin Invest. 2014. PMID: 24642465 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters